TherapeuticsMD Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TherapeuticsMD stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares.
View analyst ratings for TherapeuticsMD or view top-rated stocks.

3 Wall Street analysts have issued 12 month price targets for TherapeuticsMD's stock. Their TXMD stock forecasts range from $125.00 to $250.00. On average, they predict TherapeuticsMD's stock price to reach $187.50 in the next twelve months. This suggests a possible upside of 1,788.2% from the stock's current price.
View analysts' price targets for TherapeuticsMD or view top-rated stocks among Wall Street analysts.

TherapeuticsMD's stock was trading at $17.7750 on January 1st, 2022. Since then, TXMD shares have decreased by 44.1% and is now trading at $9.93.
View the best growth stocks for 2022 here.

TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for TherapeuticsMD.

TherapeuticsMD, Inc. (NASDAQ:TXMD) issued its quarterly earnings data on Monday, May, 16th. The company reported ($5.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.50) by $2.19. During the same quarter in the previous year, the company earned ($5.50) EPS.
View TherapeuticsMD's earnings history.

TherapeuticsMD shares reverse split on the morning of Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of TherapeuticsMD stock prior to the reverse split would have 2 shares after the split.

Some companies that are related to TherapeuticsMD include Affimed (AFMD), Khosla Ventures Acquisition (KVSA), Dyne Therapeutics (DYN), Tyra Biosciences (TYRA), Akero Therapeutics (AKRO), Lexicon Pharmaceuticals (LXRX), Biomea Fusion (BMEA), ALX Oncology (ALXO), Phathom Pharmaceuticals (PHAT), Heron Therapeutics (HRTX), PyroGenesis Canada (PYR), DiaMedica Therapeutics (DMCAF), Zymeworks (ZYME), OptiNose (OPTN) and Regulus Therapeutics (RGLS).
View all of TXMD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TXMD stock can currently be purchased for approximately $9.93.

TherapeuticsMD (NASDAQ:TXMD) has a market capitalization of $87.85 million and generates $86.95 million in revenue each year. The company earns $-172.41 million in net income (profit) each year or ($21.690010) on an earnings per share basis.

TherapeuticsMD employs 416 workers across the globe.

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The official website for TherapeuticsMD is www.therapeuticsmd.com. The company can be reached via phone at (561) 961-1900, via email at [email protected], or via fax at 561-431-3389.